Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices traded up today with the Dow Jones Industrial Average ( ^DJI) trading up 61 points (0.4%) at 16,694 as of Thursday, May 29, 2014, 3:55 PM ET. The NYSE advances/declines ratio sits at 1,757 issues advancing vs. 1,207 declining with 183 unchanged.

The Drugs industry as a whole closed the day up 0.9% versus the S&P 500, which was up 0.4%. Top gainers within the Drugs industry included Merus Labs International ( MSLI), up 6.2%, Cyanotech ( CYAN), up 7.1%, Oragenics ( OGEN), up 3.2%, Heat Biologics ( HTBX), up 1.6% and Chembio Diagnostics ( CEMI), up 2.2%.

TheStreet Ratings Group would like to highlight 3 stocks pushing the industry higher today:

Heat Biologics ( HTBX) is one of the companies that pushed the Drugs industry higher today. Heat Biologics was up $0.07 (1.6%) to $4.58 on light volume. Throughout the day, 10,340 shares of Heat Biologics exchanged hands as compared to its average daily volume of 23,300 shares. The stock ranged in a price between $4.45-$4.58 after having opened the day at $4.48 as compared to the previous trading day's close of $4.51.

Heat Biologics has a market cap of $29.4 million and is part of the health care sector. Shares are down 36.5% year-to-date as of the close of trading on Wednesday.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Highlights from TheStreet Ratings analysis on HTBX go as follows:

You can view the full analysis from the report here: Heat Biologics Ratings Report

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

At the close, Oragenics ( OGEN) was up $0.06 (3.2%) to $1.95 on light volume. Throughout the day, 3,718 shares of Oragenics exchanged hands as compared to its average daily volume of 30,500 shares. The stock ranged in a price between $1.89-$1.95 after having opened the day at $1.89 as compared to the previous trading day's close of $1.89.

Oragenics, Inc. focuses on the discovery, development, and commercialization of various technologies associated with oral health, antibiotics, and other general health benefits. Oragenics has a market cap of $68.6 million and is part of the health care sector. Shares are down 32.4% year-to-date as of the close of trading on Wednesday. Currently there is 1 analyst who rates Oragenics a buy, no analysts rate it a sell, and none rate it a hold.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

TheStreet Ratings rates Oragenics as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income and generally disappointing historical performance in the stock itself.

Highlights from TheStreet Ratings analysis on OGEN go as follows:

  • The company, on the basis of change in net income from the same quarter one year ago, has significantly underperformed when compared to that of the S&P 500 and the Biotechnology industry. The net income has significantly decreased by 54.9% when compared to the same quarter one year ago, falling from -$1.99 million to -$3.08 million.
  • Despite any intermediate fluctuations, we have only bad news to report on this stock's performance over the last year: it has tumbled by 33.69%, worse than the S&P 500's performance. Consistent with the plunge in the stock price, the company's earnings per share are down 28.57% compared to the year-earlier quarter. Naturally, the overall market trend is bound to be a significant factor. However, in one sense, the stock's sharp decline last year is a positive for future investors, making it cheaper (in proportion to its earnings over the past year) than most other stocks in its industry. But due to other concerns, we feel the stock is still not a good buy right now.
  • The company's current return on equity greatly increased when compared to its ROE from the same quarter one year prior. This is a signal of significant strength within the corporation. Compared to other companies in the Biotechnology industry and the overall market, ORAGENICS INC's return on equity significantly trails that of both the industry average and the S&P 500.
  • ORAGENICS INC's earnings per share declined by 28.6% in the most recent quarter compared to the same quarter a year ago. This company has reported somewhat volatile earnings recently. But, we feel it is poised for EPS growth in the coming year. During the past fiscal year, ORAGENICS INC continued to lose money by earning -$0.57 versus -$0.95 in the prior year. This year, the market expects an improvement in earnings (-$0.37 versus -$0.57).
  • The gross profit margin for ORAGENICS INC is currently very high, coming in at 84.60%. It has increased significantly from the same period last year. Regardless of the strong results of the gross profit margin, the net profit margin of -708.04% is in-line with the industry average.

You can view the full analysis from the report here: Oragenics Ratings Report

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Merus Labs International ( MSLI) was another company that pushed the Drugs industry higher today. Merus Labs International was up $0.09 (6.2%) to $1.54 on average volume. Throughout the day, 10,135 shares of Merus Labs International exchanged hands as compared to its average daily volume of 8,100 shares. The stock ranged in a price between $1.42-$1.54 after having opened the day at $1.45 as compared to the previous trading day's close of $1.45.

Merus Labs International Inc., a specialty pharmaceutical company, is engaged in the acquisition and licensing of branded prescription medicines in the United States, Canada, and Europe. Merus Labs International has a market cap of $79.4 million and is part of the health care sector. Shares are up 1.5% year-to-date as of the close of trading on Wednesday. Currently there are no analysts who rate Merus Labs International a buy, no analysts rate it a sell, and none rate it a hold.

TheStreet Ratings rates Merus Labs International as a sell. The area that we feel has been the company's primary weakness has been its poor profit margins.

Highlights from TheStreet Ratings analysis on MSLI go as follows:

  • The gross profit margin for MERUS LABS INTERNATIONAL INC is currently very high, coming in at 81.88%. Despite the high profit margin, it has decreased significantly from the same period last year. Despite the mixed results of the gross profit margin, MSLI's net profit margin of -21.74% significantly underperformed when compared to the industry average.
  • MERUS LABS INTERNATIONAL INC has improved earnings per share by 42.9% in the most recent quarter compared to the same quarter a year ago. The company has demonstrated a pattern of positive earnings per share growth over the past year. During the past fiscal year, MERUS LABS INTERNATIONAL INC continued to lose money by earning -$0.06 versus -$0.70 in the prior year.
  • The net income growth from the same quarter one year ago has exceeded that of the S&P 500 and greatly outperformed compared to the Pharmaceuticals industry average. The net income increased by 36.7% when compared to the same quarter one year prior, rising from -$2.30 million to -$1.46 million.
  • This stock has increased by 121.86% over the past year, outperforming the rise in the S&P 500 Index during the same period. Regarding the future course of this stock, we feel that the risks involved in investing in MSLI do not compensate for any future upside potential, despite the fact that it has seen nice gains over the past 12 months.
  • The revenue growth came in higher than the industry average of 5.3%. Since the same quarter one year prior, revenues rose by 14.4%. This growth in revenue appears to have trickled down to the company's bottom line, improving the earnings per share.

You can view the full analysis from the report here: Merus Labs International Ratings Report

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.